Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of P53 product in the different ploidy classes

Analytical Cellular Pathology

Volumn 15, Issue 1, 1997, Pages 31-45

  Leonardi, Elena ^a   Cristofori, Antonella ^a   Caffo, Orazio ^a   Dalla Palma, Paolo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Breast cancer; P53; Ploidy; Prognostic markers

Indexed keywords

DNA; HORMONE RECEPTOR; MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ANEUPLOIDY; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; DNA DETERMINATION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TRIPLOIDY;

EID: 0030819466     PISSN: 09218912     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/345949     Document Type: Article

References (51)

1. D.C. Allred, G.M. Clark, R. Elledge, S.A.W. Fukua, R.W. Brown, G.C. Chamness, C.K. Osborne and W.L. McGuire, Association of P53 protein expression with tumour cell proliferation rate and clinical outcome in node negative breast cancers, J. Natl. Cancer Inst. 85 (1993), 200-206.
2. S. Anderson, J. Fuller and Y. Lin, Cellular proliferation in breast carcinoma as determined by MIB-1 immunostaining, Am. J. Clin. Pathol. 100 (1993), 324.
3. A.D. Baildam, J. Zaloudik, A. Howell, D.M. Barnes, L. Turnbull, R. Swindell, M. Moore and R.A. Sellwood, DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast, Br. J. Cancer 55 (1987), 553-559.
4. B. Baldetorp, P.O. Bendahl, M. Fernö, K. Alanen, U. Delle, U. Falkmer, B. Hansson-Aggesjö, T. Höckenström, A. Lindgren, L. Mossberg, S. Nordling, H. Sigurdsson, O. Stål and T. Visakorpi, Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates, Cytometry 22 (1995), 115-127.
5. M. Barbareschi, E. Leonardi, F.A. Mauri, G. Serio and P. Dalla Palma, P53 and c-erbB-2 expression in breast carcinoma: an immunohistochemical study with correlations to receptor status, proliferation markers, and clinical stage in human breast carcinoma, Am. J. Clin. Pathol. 98 (1992), 408-418.
6. N.J. Barnard, P.A. Hall, N.R. Lemoine and N. Kadar, Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to pathological and clinical variables, J. Pathol. 152 (1987), 287-295.
7. E. Bergers, P.J. van Diest and J.P.A. Baak, Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material, Cancer 77 (1996), 2258-2266.
8. H.J.G. Bloom and W.W. Richardson, Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years, Br. J. Cancer 11 (1957), 359-377.
9. N. Bouzubar, K.J. Walker and K. Griffiths, Ki-67 immunostaining in primary breast cancer: pathological and clinical associations, Br. J. Cancer 59 (1989), 943-947.
10. R.S. Camplejohn, C.M. Ash, C.E. Gillet, B. Raikundalia, D.M. Barnes, W.M. Gregory, M.A. Richards and R.R. Millis, The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre, Br. J. Cancer 71 (1995), 140-145.
11. G. Cattoretti, M.H.G. Becker and G. Key, Monoclonal antibody against recombinant part of Ki67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin fixed paraffin embedded sections, J. Pathol. 168 (1992), 357-363.
12. B. Chevallier, F. Heintzmann and V. Mosseri, Prognostic value of oestrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis, Cancer 62 (1988), 2517-2524.
13. G.M. Clark, W.L. McGuire, C.A. Hubay, O.H. Pearson and J.S. Marshall, Progesterone receptor as a prognostic factor in stage II breast cancer, N. Engl. J. Med. 309 (1983), 1343-1347.
14. B. Fisher, N. Gunduz, J. Costantino, E.R. Fisher, C. Redmond, E.P. Mamounas and R. Siderits, DNA flow cytometric analysis of primary operable breast cancer: relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04, Cancer 68 (1991), 1465-1475.
15. J. Gerdes, H. Lemke, H. Baisch, H.H. Wacker, U. Schwab and H. Stein, Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67, J. Immunol. 133 (1984), 1710-1715.
16. W. Giaretti, A model of DNA aneuploidization and evolution in colorectal cancer, Lab. Invest. 71 (1994), 904-910.
17. W.L. Gullik, The role of the epidermal growth factor receptor and c-erbB-2 protein in breast cancer, Int. J. Cancer 5 (1990), 55-61.
18. D.W. Hedley, G.M. Clark, C.J. Cornelisse, D. Killander, T. Kute and D. Merkel, Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast, Cytometry 14 (1993), 482-485.
19. J. Hurlimann, Prognostic value of P53 protein expression in breast carcinomas, Path. Res. Pract. 189 (1993), 996-1003.
20. J. Isola, T. Visakorpi, K. Holli and O.P. Kallionemi, Association of overexpression of tumour suppressor protein P53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients, J. Natl. Cancer Inst. 84 (1992), 1109-1114.
21. A.A. Keshgegian and A. Cnaan, Proliferation markers in breast carcinoma, Am. J. Clin. Pathol. 104 (1995), 42-49.
22. R. Kimmig, H. Spelsberg, T. Kapsner, M. Untch and H. Hepp, Flow cytometric DNA analysis of breast cancer by two colour method using cytokeratin labeling for identification of tumour cells, Anal. Cell. Pathol. 7 (1994), 205-215.
23. G. Lanza, I. Maestri, A. Dubini, R. Gafa', A. Santini, S. Ferretti and L. Cavazzini, P53 expression in colorectal cancer. Relation to tumour type, DNA ploidy pattern, and short term survival, Am. J. Clin. Pathol. 105 (1996), 604-612.
24. G. MacGrogan, F. Bonichon, I. DeMascarel, M. Trojani, M. Durand, A. Avril and J.M. Coindre, Prognostic value of P53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases, Breast Cancer Res. Treat. 36 (1995), 71-81.
25. G. Mazzini and M. Danova, Citometria a flusso. Applicazioni cliniche dell'analisi del DNA in oncologia, in: I Manuali delle Scuole, Pavia, ed., 1994.
26. W.L. McGuire, Steroid hormone receptors in breast cancer treatment strategy, Recent Prog. Horm. Res. 36 (1980), 135-156.
27. G.I. Meling, R.A. Lothe, A.L. Børresen, C. Graue, S. Hauge, O.P.F. Clausen and T.O. Rognum, The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinico-pathological variables, Br. J. Cancer 67 (1993), 93-98.
28. S.M. O'Reilly, R.S. Camplejohn, D.M. Barnes, R.R. Millis, D. Allen, R.D. Rubens and M.A. Richards, DNA index, S-phase fraction, histological grade and prognosis in breast cancer, Br. J. Cancer 61 (1990), 671-674.
29. A. Pich, E. Margaria, L. Chiusa, R. Ponti and M. Geuna, DNA ploidy and P53 expression correlated with survival and cell proliferative activity in male breast cancer, Hum. Pathol. 27 (1996), 676-682.
30. G.P. Rosanelli, P. Steindorf, G.H. Wirnsberger, M. Klimpflinger, M. Ratschek, P. Puerstner, H. Auner and A. Berthold, Mutant P53 expression and DNA analysis in human breast cancer; comparison with conventional clinico-pathologic parameters, Anticancer Res. 15 (1995), 581-586.
31. H. Schimmelpenning, E.T. Eriksson, A. Zetterberger and G.U. Auer, Association of immunohistochemical P53 tumour suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas, World J. Surg. 18 (1994), 827-833.
32. S.E. Shackney, G. Berg, S.R. Simon, J. Cohen, S. Amina, W. Pommersheim, R. Yakulis, S. Wang, M. Uhl, C.A. Smith, A.A. Pollice and R.J. Hartsock, Origins and clinical implications of aneuploidy in early bladder cancer, Cytometry 22 (1995), 307-316.
33. T.V. Shankey, P.S. Rabinovitch, B. Bagwell, K.D. Bauer, R.E. Duque, D.W. Hedley, B.H. Mayall and L. Wheeless, Guidelines for implementation of clinical DNA cytometry, Cytometry 14 (1993), 472-477.
34. S.R. Shi, M.E. Key and K.L. Kaira, Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections, J. Histochem. Cytochem. 39 (1991), 741-748.
35. T.P. Singleton and J.G. Strickler, Clinical and pathological significance of the c-erbB-2 (HER-2/neu) oncogene, Pathol. Annu. 27 (1992), 165-190.
36. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987), 177-182.
37. B. Spiessl, TNM-Atlas: An Illustrated Guide to the TNM/pTNM-Classification of Malignant Tumours, Springer, New York, 1989, pp. 174-183.
38. M. Stenmark-Askmalm, O. Stal, K. Olsen and B. Nordenskjold, P53 as a prognostic factor in stage I breast cancer, Br. J. Cancer 72 (1995), 715-719.
39. A.D. Thor, D.H. Moore II, S.M. Edgerton, E.S. Kawasaki, E. Reihsaus, H.T. Lynch, J.N. Marcus, L. Schwartz, L.C. Chen, B.H. Mayall and H.S. Smith, Accumulation of P53 tumour suppressor gene protein: an independent marker of prognosis in breast cancer, J. Natl. Cancer Inst. 84 (1992), 845-855.
40. S.M. Veronese, M. Barbareschi, L. Morelli, A. Aldovini, F.A. Mauri, O. Caffo, M. Gambacorta and P. Dalla Palma, Predictive value of ER1D5 antibody immunostaining in breast cancer, Appl. Immunohistochem. 3 (1995), 85-90.
41. D.W. Visscher, P. Sochacki, S. Ottosen, S. Wykes and J.D. Crissman, Assessment and significance of diploid-range epithelial populations in DNA aneuploid breast carcinomas using multi-parametric flow cytometry, Anal. Cell. Pathol. 8 (1995), 267-277.
42. D.W. Visscher, R.J. Zarbo, K.A. Greenwald and J.D. Crissman, Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast, Pathol. Annu. (Part I) 25 (1990), 171-210.
43. D.W. Visscher, R.J. Zarbo, G. Jacobsen, A. Kambouris, G. Talpos, W. Sakr and J.D. Crissman, Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry, Lab. Invest. 62 (1990), 370-378.
44. R.P. Wersto, R.L. Liblit and L.G. Koss, Solid tumours: a review of the interpretation of DNA histograms, Hum. Pathol. 22 (1991), 1085-1098.
45. C. Wiltschke, I. Kindas-Muegge, A. Steininger, A. Reiner, G. Reiner and P.N. Preis, Coexpression of Her-2/Neu and P53 is associated with a shorter disease-free survival in node-positive breast cancer patients, J. Cancer Res. Clin. Oncol. 120 (1994), 737-742.
46. S. Wingren, O. Stål, J. Carstensen, X.F. Sun and B. Nordenskjöld, S-phase determination immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence, Breast Cancer Res. Treat. 29 (1993), 179-187.
47. S. Wingren, O. Stål and B. Nordenskjöld, Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin, Br. J. Cancer 69 (1994), 546-549.
48. S. Wingren, O. Stål, S. Sullivan, A. Brisfors and B. Nordenskjöld, S-phase fraction after gating on epithelial cells predicts recurrence in node-negative breast cancer, Int. J. Cancer 59 (1994), 7-10.
49. R.J. Zarbo, R.D. Brown, M.D. Linden, F.X. Torres, R.E. Nakhleh and D.S. Schultz, Rapid (one-shot) staining method for two-color multiparametric DNA flow cytometric analysis of carcinomas using staining for cytokeratin and leukocyte common antigen, Am. J. Clin. Pathol. 101 (1994), 638-642.
50. R.J. Zarbo, D.W. Visscher and J.D. Crissman, Two-color multiparametric method for flow cytometric DNA analysis of carcinomas using staining for cytokeratin and leukocyte-common antigen, Anal. Quant. Cytol. Histol. 11 (1989), 391-402.
51. I. Zbieranowski, C. Demianiuk, V. Bell, W.A. Knape and D. Murray, Detection of false DNA aneuploidy and false DNA multiploidy in flow cytometric DNA analysis, Anal. Cell. Pathol. 5 (1993), 69-84.